Structure Therapeutics’ Oral GLP-1 Trial Results Intensify Competition for Novo Nordisk in the Obesity Drug Market

Novo Nordisk is facing fresh competitive pressure after new mid-stage clinical data from Structure Therapeutics suggested that its experimental oral obesity treatment could deliver weight-loss results broadly in line with Novo’s own pill-based obesity therapy. According to Proactive Investors, citing analyst commentary from Citi, the latest findings add to growing concerns that the obesity drug market may become more crowded and more competitive over the coming years.

Why this development matters

The obesity treatment market has become one of the most closely watched areas in global healthcare, driven by surging demand for GLP-1-based medicines that help patients lose weight and improve metabolic health. Novo Nordisk has been one of the sector’s biggest beneficiaries, with its obesity franchise attracting strong investor attention. However, that success has also invited a wave of challengers, and the latest data from Structure Therapeutics appears to be one more sign that Novo may not have the field to itself for long.

Proactive reported that Citi retained a “neutral” stance on Novo Nordisk shares after reviewing updated phase II trial results from Structure’s ACCESS obesity programme. The bank said the data pointed to weight loss levels that were broadly comparable to Novo’s own oral obesity drug results, which is important because pill-based therapies are seen as a highly attractive alternative to injectable treatments for many patients.

What Structure Therapeutics reported

Updated phase II ACCESS obesity programme data

Structure Therapeutics released updated results for aleniglipron, an oral small-molecule GLP-1 drug candidate. The data showed that patients receiving the 180mg dose achieved 16.3% placebo-adjusted weight loss at 44 weeks. Meanwhile, patients on the 120mg dose recorded up to 16.2% placebo-adjusted weight loss at 56 weeks. These figures caught market attention because they sit in a range that compares favorably with established expectations for advanced obesity medicines.

The phrase “placebo-adjusted” is important here. It means the reported figure reflects the difference between the treatment group and the placebo group, helping analysts judge the real effect of the medicine rather than weight changes that might happen through diet, exercise, or other non-drug factors during the trial. That makes the comparison more meaningful for investors and industry observers evaluating how powerful a treatment may ultimately prove in the market. The source article specifically highlighted these placebo-adjusted outcomes as the main benchmark used by Citi in assessing competitive pressure on Novo Nordisk.

Comparison with Novo Nordisk’s obesity pill

For context, Proactive said Novo Nordisk’s Wegovy Pill delivered 13.9% placebo-adjusted weight loss at 64 weeks. On a headline basis, that puts Structure’s updated phase II data in the same ballpark and, in some dose cohorts, numerically ahead. While these numbers do not prove that Structure’s candidate is superior, they do suggest that rival oral options are advancing to a level where they can no longer be dismissed as distant threats.

That matters because the oral obesity drug segment is widely viewed as one of the next big battlegrounds in pharmaceutical innovation. Injectable GLP-1 medicines have already transformed treatment, but many doctors, patients, and payers may prefer pills if efficacy, safety, convenience, and adherence line up in a compelling way. A successful oral medicine could dramatically expand access and reshape prescribing habits. This is why even early or mid-stage data can move sentiment around companies such as Novo Nordisk. The comparison cited by Proactive is therefore not just about one dataset; it reflects a broader strategic contest for leadership in a massive future market.

The two details Citi said investors should watch

1. No sign of a weight-loss plateau

One of the most striking points raised by Citi was that there appeared to be no clear plateau across doses in Structure’s trial data. In simple terms, patients did not seem to have reached an obvious ceiling in their weight-loss response during the observed period. That could be meaningful, because it suggests longer treatment durations might potentially lead to further reductions in body weight if the trend continues in later studies.

For investors, this matters because obesity drugs are often judged not only by how much weight they help patients lose, but also by whether that effect keeps building over time or levels off too quickly. A treatment that continues to deliver progressive results may be more attractive commercially and clinically, provided safety stays manageable. Citi did not present this as a certainty, but it clearly flagged the trend as a potentially significant feature of the dataset.

2. Lower discontinuation rates due to side effects

The second feature highlighted by Citi involved tolerability. According to Proactive’s report, treatment discontinuations due to side effects were below 4% across Structure’s datasets. By comparison, Novo’s Wegovy Pill showed a discontinuation rate of 6.9%. At the same time, rates of nausea and vomiting were described as broadly similar between the datasets.

That is a notable point because side effects are one of the biggest commercial and clinical issues for GLP-1 therapies. Even highly effective drugs can face adoption barriers if too many patients stop treatment early. Lower discontinuation rates may suggest a more manageable patient experience, though it is still too early to draw firm conclusions. Even so, when efficacy appears competitive and tolerability looks encouraging, the investment market tends to pay close attention.

Why analysts are still being cautious

Phase II data is promising, but not final

Despite the encouraging numbers, Citi was careful not to overstate the result. Proactive noted that the bank emphasized a basic but important limitation: phase II data is preliminary. Drug development is full of examples where promising mid-stage results did not fully carry through into larger, later-stage studies. That means Structure still has substantial work ahead before aleniglipron could be considered a proven commercial challenger.

Large phase III studies are designed to confirm efficacy and safety in broader patient populations and under stricter regulatory expectations. Until those trials are completed, comparisons between companies must be treated with caution. Trial design, patient characteristics, dosing schedules, adherence, and measurement periods can all influence results. A numerical edge in one study does not automatically translate into better real-world performance or regulatory success. Citi’s message, as reported, was balanced: the threat looks real, but it is not yet fully validated.

Phase III is expected in the second half of 2026

Structure Therapeutics expects to begin its phase III programme in the second half of 2026, according to the Proactive report. That timeline is significant because it sets the stage for the next major test of the drug’s competitive potential. Until then, the investment case rests heavily on expectations, trend analysis, and confidence in execution rather than definitive late-stage proof.

For Novo Nordisk, this means the immediate threat is more about investor perception and long-term market modeling than near-term revenue displacement. But markets usually look ahead. If more competitors continue to report credible oral obesity data, investors may begin assigning lower future market share assumptions to today’s leaders. That is exactly why even preliminary rival results can weigh on sentiment around established players. This interpretation follows from the facts reported by Proactive and Citi’s maintained cautious stance.

Citi keeps its “neutral” rating on Novo Nordisk

After reviewing the new information, Citi maintained its “neutral” rating on Novo Nordisk. That suggests the bank is not turning outright negative on the stock, but it is also not ready to become more optimistic in light of rising competition. In other words, Novo remains a major force in obesity treatment, yet the path ahead may be less straightforward than before.

The bank also kept a “high risk” designation alongside that neutral rating. According to the article, this reflects Citi’s view that long-term competitive pressure on Novo’s obesity franchise is a genuine issue for investors to consider. That wording is especially telling. It signals that the market opportunity remains huge, but so does the strategic risk if rivals narrow the gap in efficacy, convenience, or side-effect profile.

What this could mean for Novo Nordisk’s obesity franchise

A bigger race in oral obesity medicine

Novo Nordisk has been one of the best-known names in obesity care, but the latest report underlines a larger industry shift: the race is moving beyond injectables and increasingly toward oral options. A strong pill can be easier to distribute, easier for some patients to accept, and easier to fit into daily life. That creates a huge incentive for biotech and pharmaceutical companies to develop oral GLP-1 treatments that can match or approach injectable outcomes.

If rivals such as Structure Therapeutics continue to generate compelling data, Novo may face tougher pricing dynamics, more intense competition for prescriber attention, and more pressure to demonstrate differentiation. That differentiation could come from efficacy, safety, convenience, dosing flexibility, manufacturing scale, or brand trust. But the days of assuming one or two dominant players may be fading as the field matures. This is an inference based on the competitive concerns specifically discussed in the cited report.

Investor sentiment may become more selective

For investors, a more crowded obesity drug market does not automatically mean a weak future for Novo Nordisk. Demand remains enormous, and the company still holds a powerful position in the category. However, the bar for valuation support may rise. Investors may become more selective, rewarding companies that show durable advantages rather than simply rewarding exposure to the GLP-1 boom. Citi’s continued neutral view and high-risk designation reflect that more measured mindset.

This means future updates could matter a great deal. Late-stage trial data, commercial launches, regulatory milestones, manufacturing capacity, and comparative tolerability trends may all shape how the market values leaders and challengers alike. In fast-growing therapeutic areas, leadership can remain strong while still becoming more contested. That appears to be the broader message behind the reaction described in the Proactive piece.

Broader implications for the obesity drug sector

The bigger story here is not limited to one stock or one clinical update. The obesity treatment space is rapidly evolving into one of the most strategically important segments in global pharmaceuticals. New entrants are trying different formulations, dose strategies, and drug designs to improve patient outcomes and convenience. The fact that a rival oral small-molecule GLP-1 candidate is already generating data comparable to a major incumbent’s pill result shows how quickly the science and competition are moving.

This could ultimately benefit patients if it leads to more choices, better tolerated treatments, stronger efficacy, and broader availability. It could also pressure companies to innovate faster and prove value more clearly. For the market, however, more choice can also mean more uncertainty, especially when several promising contenders are still moving through different stages of development. That mix of opportunity and risk is exactly why analysts are parsing each data release so carefully. The cited report captures that tension clearly.

Detailed market reading of the latest update

Seen in full, the latest development creates a layered picture. First, Structure Therapeutics has produced data strong enough to force comparison with Novo Nordisk’s own oral obesity results. Second, the trial appears to show not only competitive weight-loss outcomes but also encouraging signals on durability and discontinuation rates. Third, analysts are deliberately stopping short of drawing final conclusions because phase II evidence is not the last word. And fourth, the result still matters because perception of future competition can influence how investors assess long-term franchise strength today.

That combination explains why Citi did not change its rating while still stressing risk. The bank is effectively saying that Novo Nordisk remains a serious player with substantial assets, but the company’s obesity leadership should no longer be viewed in isolation from an expanding field of capable rivals. In competitive therapeutic markets, sentiment often changes before revenue does. This looks like one of those moments.

Conclusion

Structure Therapeutics’ updated phase II results for aleniglipron have injected fresh energy into the race for oral obesity treatments. The data, as summarized by Proactive Investors, showed placebo-adjusted weight loss of 16.3% at 44 weeks on the 180mg dose and up to 16.2% at 56 weeks on the 120mg dose, versus 13.9% at 64 weeks for Novo Nordisk’s Wegovy Pill. Citi highlighted two especially important takeaways: the absence of a clear weight-loss plateau and discontinuation rates below 4%, compared with 6.9% for Novo’s pill, while also warning that phase II data remains preliminary.

As a result, Citi kept its neutral rating on Novo Nordisk and maintained a high-risk designation, pointing to genuine long-term competitive pressure on the company’s obesity franchise. The immediate takeaway is not that Novo has lost its edge, but that the market is becoming more contested, especially in oral GLP-1 therapies. For investors, analysts, and healthcare observers, this is another clear sign that the obesity drug race is entering a more demanding and more competitive phase. For reference, the original report was published by Proactive Investors on 17 March 2026.

Source referenced: Proactive Investors.

#NovoNordisk #StructureTherapeutics #GLP1 #ObesityDrugMarket #SlimScan #GrowthStocks #CANSLIM